PDF(953 KB)
Regulatory effects of mesenchymal stem cells on B1 cells and Tfh cells in children with systemic lupus erythematosus
Zhou SHE, Fei-Feng WU, Jue-Yi MAO, Chuan WEN
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (2) : 242-249.
PDF(953 KB)
PDF(953 KB)
Regulatory effects of mesenchymal stem cells on B1 cells and Tfh cells in children with systemic lupus erythematosus
Objective To investigate B1 cell and follicular helper T (Tfh) levels in children with systemic lupus erythematosus (SLE) and to assess whether mesenchymal stem cells (MSCs) regulate peripheral blood B1 cells and Tfh cells in pediatric SLE. Methods Peripheral blood mononuclear cells (PBMCs) were isolated from children with SLE and from controls. B1 and Tfh cells were measured, differences between groups were analyzed, and correlations with clinical indices were evaluated. Human umbilical cord mesenchymal stem cells (hUCMSCs) were co-cultured with PBMCs for 48 hours at hUCMSC:PBMC ratios of 1:10 and 1:20, with PBS-treated PBMCs as control; post-culture proportions of B1 and Tfh cells were re-assessed. Results hUCMSCs adhered to plastic with spindle-shaped morphology, showed robust growth, and exhibited osteogenic and adipogenic differentiation. B1 and Tfh cell levels were higher in children with SLE than in controls (P<0.05) and were not significantly correlated with serum complement, immunoglobulins, antibody levels, or SLE Disease Activity Index scores (P>0.05). Tfh cells showed a trend toward association with serum C4 and IgM. After co-culture, no statistically significant differences in B1 or Tfh cell proportions were detected among the PBS control and hUCMSC co-culture groups (P>0.05). Conclusions B1 cells and Tfh cells differ between children with SLE and controls and may be involved in SLE pathogenesis. hUCMSCs do not appear to exert therapeutic effects in SLE by regulating peripheral blood B1 and Tfh cell numbers.
Systemic lupus erythematosus / Mesenchymal stem cell / B1 cell / Tfh cell / Child
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
中国狼疮肾炎诊治和管理指南工作组, 国家肾脏疾病临床医学研究中心. 中国狼疮肾炎诊治和管理指南(2025版)[J]. 中华医学杂志, 2025, 105(22): 1783-1819. DOI: 10.3760/cma.j.cn112137-20250327-00748 .
|
| [10] |
中华医学会风湿病学分会, 中国医院协会临床新技术应用专业委员会. 异体间充质干细胞治疗系统性红斑狼疮专家共识[J]. 中华风湿病学杂志, 2022, 26(1): 1-8. DOI: 10.3760/cma.j.cn141217-20210923-00381 .
|
| [11] |
白茹, 戚燕, 吕昭萍, 等. 脐带间充质干细胞移植治疗难治性系统性红斑狼疮3年随访[J]. 中国免疫学杂志, 2017, 33(6): 905-909. DOI: 10.3969/j.issn.1000-484X.2017.06.020 .
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
梁军, 孙凌云. 间充质干细胞治疗系统性红斑狼疮的基础和临床研究[J]. 浙江医学, 2017, 39(21): 1836-1841. DOI: 10.12056/j.issn.1006-2785.2017.39.21.2017-1690 .
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
陈俊伟, 景晓娜, 郝美华, 等. 系统性红斑狼疮患者CD5+B细胞的变化及其意义[J]. 中华风湿病学杂志, 2017, 21(8): 513-517,
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
所有作者声明无利益冲突。